Our study suggests that targeting mitochondrial dysfunction in PCOS may be necessary to improve insulin resistance and that hyperandrogenemia blunts the beneficial effect of SGLT2 inhibitors in the HAF rat model of PCOS. The gene discussed is SLC5A2; the disease is polycystic ovary syndrome.